Danegaptide

Drug Profile

Danegaptide

Alternative Names: GAP-134; GAP-Oral; ZP 1609

Latest Information Update: 24 Mar 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Zealand Pharma
  • Developer Wyeth; Zealand Pharma
  • Class Antiarrhythmics; Cytoprotectives; Dipeptides; Small molecules
  • Mechanism of Action Gap junction modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Atrial fibrillation; Myocardial reperfusion injury

Most Recent Events

  • 02 Mar 2016 Discontinued - Phase-II for Myocardial reperfusion injury (Prevention) in Denmark (IV)
  • 01 Dec 2015 Zealand Pharma completes a phase II trial in Myocardial reperfusion injury (Prevention) in Denmark (NCT01977755)
  • 28 Aug 2015 Zealand Pharma completes enrolment in its phase II trial for Myocardial reperfusion injury (Prevention) in Denmark (9183656; EudraCT2013-002312-27; NCT01977755)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top